NVK002 (Vyluma)
Slowing progression of pediatric myopia
Phase 3Active
Key Facts
About Nevakar
Nevakar is a private, clinical-stage biotech company repositioning established drugs for improved outcomes in ophthalmology through novel formulations and delivery systems. Its strategy leverages known active ingredients to potentially accelerate development and reduce risk. The company's most advanced program, NVK002 for pediatric myopia progression, is under regulatory review in China and has completed Phase 3 trials in the US, positioning it as a near-term catalyst. Nevakar's business model spans both therapeutics and a proprietary drug delivery platform.
View full company profile